To identify biomarker/s associated with ADA response to adalimumab we examined the surface immune-signature of PMBCs isolated from 10 ADA− to 10 ADA+ RA patients treated with adalimumab for a minimum of 12 months (Table 1). The gene discussed is ADA; the disease is rheumatoid arthritis.